<?xml version='1.0' encoding='utf-8'?>
<document id="28716728"><sentence text="Cytochrome P450 3A selectively affects the pharmacokinetic interaction between erlotinib and docetaxel in rats."><entity charOffset="79-88" id="DDI-PubMed.28716728.s1.e0" text="erlotinib" /><entity charOffset="93-102" id="DDI-PubMed.28716728.s1.e1" text="docetaxel" /><pair ddi="false" e1="DDI-PubMed.28716728.s1.e0" e2="DDI-PubMed.28716728.s1.e0" /><pair ddi="false" e1="DDI-PubMed.28716728.s1.e0" e2="DDI-PubMed.28716728.s1.e1" /></sentence><sentence text="Erlotinib as a first-line drug is used in non-small cell lung cancer (NSCLC) patients with sensitive EGFR mutations, while resistance to this drug will occur after several years of treatment"><entity charOffset="0-9" id="DDI-PubMed.28716728.s2.e0" text="Erlotinib" /></sentence><sentence text=" Therefore, the microtubule disturber docetaxel is introduced as combined regimen in clinical trials"><entity charOffset="38-47" id="DDI-PubMed.28716728.s3.e0" text="docetaxel" /></sentence><sentence text=" This report investigated the potentials and mechanisms of drug-drug interaction (DDI) between erlotinib and docetaxel using wild type (WT) and Cyp3a1/2 knockout (KO) rats"><entity charOffset="95-104" id="DDI-PubMed.28716728.s4.e0" text="erlotinib" /><entity charOffset="109-118" id="DDI-PubMed.28716728.s4.e1" text="docetaxel" /><pair ddi="false" e1="DDI-PubMed.28716728.s4.e0" e2="DDI-PubMed.28716728.s4.e0" /><pair ddi="false" e1="DDI-PubMed.28716728.s4.e0" e2="DDI-PubMed.28716728.s4.e1" /></sentence><sentence text=" The erlotinib O-demethylation and docetaxel hydroxylation reactions in the absence or the presence of another drug were analyzed in vitro via the assay of rat liver microsomes"><entity charOffset="35-44" id="DDI-PubMed.28716728.s5.e0" text="docetaxel" /></sentence><sentence text=" In whole animal studies, erlotinib and docetaxel were given to WT and KO rats individually or jointly, and the pharmacokinetic profiles of these two drugs were analyzed and compared among different groups"><entity charOffset="26-35" id="DDI-PubMed.28716728.s6.e0" text="erlotinib" /><entity charOffset="40-49" id="DDI-PubMed.28716728.s6.e1" text="docetaxel" /><entity charOffset="71-73" id="DDI-PubMed.28716728.s6.e2" text="KO" /><pair ddi="false" e1="DDI-PubMed.28716728.s6.e0" e2="DDI-PubMed.28716728.s6.e0" /><pair ddi="false" e1="DDI-PubMed.28716728.s6.e0" e2="DDI-PubMed.28716728.s6.e1" /><pair ddi="false" e1="DDI-PubMed.28716728.s6.e0" e2="DDI-PubMed.28716728.s6.e2" /><pair ddi="false" e1="DDI-PubMed.28716728.s6.e1" e2="DDI-PubMed.28716728.s6.e1" /><pair ddi="false" e1="DDI-PubMed.28716728.s6.e1" e2="DDI-PubMed.28716728.s6.e2" /></sentence><sentence text=" The results showed that docetaxel not only inhibited the CYP3A-mediated biotransformation of erlotinib in vitro, but also significantly increased the maximum concentration and systemic exposure of erlotinib in vivo in WT rats"><entity charOffset="25-34" id="DDI-PubMed.28716728.s7.e0" text="docetaxel" /><entity charOffset="94-103" id="DDI-PubMed.28716728.s7.e1" text="erlotinib" /><entity charOffset="198-207" id="DDI-PubMed.28716728.s7.e2" text="erlotinib" /><pair ddi="false" e1="DDI-PubMed.28716728.s7.e0" e2="DDI-PubMed.28716728.s7.e0" /><pair ddi="false" e1="DDI-PubMed.28716728.s7.e0" e2="DDI-PubMed.28716728.s7.e1" /><pair ddi="false" e1="DDI-PubMed.28716728.s7.e0" e2="DDI-PubMed.28716728.s7.e2" /><pair ddi="false" e1="DDI-PubMed.28716728.s7.e1" e2="DDI-PubMed.28716728.s7.e1" /><pair ddi="false" e1="DDI-PubMed.28716728.s7.e1" e2="DDI-PubMed.28716728.s7.e2" /></sentence><sentence text=" In contrast, the DDI was significantly attenuated in KO rats"><entity charOffset="54-62" id="DDI-PubMed.28716728.s8.e0" text="KO" /></sentence><sentence text=" On the other hand, erlotinib did not influence docetaxel either in vitro biotransformation or in vivo pharmacokinetic behaviors"><entity charOffset="20-29" id="DDI-PubMed.28716728.s9.e0" text="erlotinib" /><entity charOffset="48-57" id="DDI-PubMed.28716728.s9.e1" text="docetaxel" /><pair ddi="false" e1="DDI-PubMed.28716728.s9.e0" e2="DDI-PubMed.28716728.s9.e0" /><pair ddi="false" e1="DDI-PubMed.28716728.s9.e0" e2="DDI-PubMed.28716728.s9.e1" /></sentence><sentence text=" These results exhibited the potentials of erlotinib-docetaxel interaction and indicated that the CYP3A played the perpetrating role of docetaxel on erlotinib in rats"><entity charOffset="43-52" id="DDI-PubMed.28716728.s10.e0" text="erlotinib" /><entity charOffset="136-145" id="DDI-PubMed.28716728.s10.e1" text="docetaxel" /><entity charOffset="149-158" id="DDI-PubMed.28716728.s10.e2" text="erlotinib" /><pair ddi="false" e1="DDI-PubMed.28716728.s10.e0" e2="DDI-PubMed.28716728.s10.e0" /><pair ddi="false" e1="DDI-PubMed.28716728.s10.e0" e2="DDI-PubMed.28716728.s10.e1" /><pair ddi="false" e1="DDI-PubMed.28716728.s10.e0" e2="DDI-PubMed.28716728.s10.e2" /><pair ddi="false" e1="DDI-PubMed.28716728.s10.e1" e2="DDI-PubMed.28716728.s10.e1" /><pair ddi="false" e1="DDI-PubMed.28716728.s10.e1" e2="DDI-PubMed.28716728.s10.e2" /></sentence><sentence text=" A better understanding of this DDI with CYP3A may help the regulation of the use of these two drugs, avoid potential problems, and adjust dose carefully and early in clinic" /><sentence text="" /></document>